Print this page

Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).

Primary Objective:
The primary endpoint of this three-arm, parallel phase II study is the percentage of patients receiving 1, 2, 3 and 4 (up to 6 for patients with head and neck cancer) combination chemoimmunotherapy (described in the Schema as Chemo/P) cycles.

Secondary Objectives:
1. Overall response rates (at 6 weeks, and best response)

2. Safety/tolerability

3. Progression Free Survival

Protocol Number: 032201
Phase: Phase II
Applicable Disease Sites: Lung
Drugs Involved: 5-Fluorouracil
PEMETREXED
Nab-paclitaxel
CARBOPLATIN
Pembrolizumab (MK-3475)
PACLITAXEL
Scope: Local
Therapies Involved: Chemotherapy multiple agents systemic
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
    • Principal Investigator
      • Missak Haigentz MD
  • RWJBarnabas Health
    • Community Medical Center
    • Cooperman Barnabas, Livingston
    • Jersey City Medical Center, Jersey City
    • Monmouth Medical Center
    • Monmouth Medical Center Southern Campus
    • Newark Beth Israel Medical Center
    • Robert Wood Johnson University Hospital, Hamilton
    • Robert Wood Johnson University Hospital, Somerset
    • Trinitas Hospital and Comprehensive Cancer Center
  • Rutgers Cancer Institute of New Jersey-University Hospital
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.